Teladoc Health (TDOC) officer discloses RSU vesting and tax-related share sale

Rhea-AI Filing Summary

Teladoc Health, Inc. officer reports stock unit vesting and tax-sale transaction. A Teladoc Health executive, serving as President, U.S. Group Health, reported the conversion of performance stock units and restricted stock units into common stock and a related sale of shares.

On 12/01/2025, 1,189 performance stock units and two blocks of restricted stock units totaling 8,346 units (3,488 and 4,858) converted into the same number of Teladoc common shares on a one-for-one basis. On 12/02/2025, 4,582 shares of common stock were sold at $7.488 per share to cover tax withholding obligations from these vestings.

After these transactions, the reporting person beneficially owned 60,054 shares of Teladoc common stock directly, along with remaining derivative holdings that include performance and restricted stock units scheduled to vest over time under prior grants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bliss Kelly

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Group Health

3. Date of Earliest Transaction (Month/Day/Year)
12/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/01/2025		M		1,189	A	(1)	56,290	D
Common Stock	12/01/2025		M		3,488	A	(2)	59,778	D
Common Stock	12/01/2025		M		4,858	A	(2)	64,636	D
Common Stock	12/02/2025		S		4,582(3)	D	$7.488	60,054	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	(1)	12/01/2025		M			1,189	(4)	(4)	Common Stock	1,189	$0	1,186	D
Restricted Stock Units	(2)	12/01/2025		M			3,488	(5)	(5)	Common Stock	3,488	$0	3,488	D
Restricted Stock Units	(2)	12/01/2025		M			4,858	(6)	(6)	Common Stock	4,858	$0	24,293	D

Explanation of Responses:

1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.

2. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.

4. On March 1, 2024, the reporting person earned 14,263 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

5. On March 3, 2023, the reporting person was granted 41,853 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

6. On March 19, 2024, the reporting person was granted 58,300 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Teladoc Health (TDOC) report in this Form 4?

The filing reports an executive’s performance stock units and restricted stock units converting into Teladoc common stock, and a subsequent sale of shares to cover tax withholding obligations.

How many Teladoc (TDOC) shares were sold by the insider and at what price?

The reporting person sold 4,582 shares of Teladoc common stock at a price of $7.488 per share to satisfy tax withholding related to stock unit vesting.

How many Teladoc (TDOC) stock units vested in this transaction?

A total of 1,189 performance stock units and two restricted stock unit grants of 3,488 and 4,858 units each vested, converting one-for-one into Teladoc common shares.

What is the insider’s role at Teladoc Health (TDOC)?

The reporting person is an officer of Teladoc Health, serving as President, U.S. Group Health.

How many Teladoc (TDOC) shares does the insider own after these transactions?

Following the reported transactions, the insider directly beneficially owned 60,054 shares of Teladoc common stock.

Were the Teladoc (TDOC) stock units granted under long-term incentive plans?

Yes. The performance stock units and restricted stock units were granted in prior years and vest over time in scheduled installments under Teladoc’s equity award programs.